Macular Edema – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Macular edema is a pathological condition characterized by the accumulation of fluid in the macula, a central region of the retina responsible for high-resolution vision. It is commonly observed in conjunction with medical conditions such as diabetic retinopathy, macular degeneration, or retinal vein occlusion, where abnormal leakage of fluid from retinal blood vessels occurs, resulting in macular swelling. Symptoms of macular edema typically include visual impairments such as blurred or distorted vision, difficulty reading, and the perception of straight lines appearing wavy. Additionally, individuals may experience a central dark or empty spot in their field of vision. To diagnose macular edema, a comprehensive eye examination is typically conducted, which may involve tests to assess visual acuity, dilation of the pupils to examine the inner eye structures, utilization of optical coherence tomography (OCT) or fluorescein angiography. However, macular edema cannot be cured entirely. Various treatment options are available depending on the underlying cause and severity of the condition. Common approaches include the administration of anti-inflammatory like corticosteroids or anti-vascular endothelial growth factor (anti-VEGF) drugs through eye injections to alleviate swelling and fluid leakage. Laser therapy and vitrectomy are also employed as treatment modalities.
·
The reported prevalence of diabetic macular
edema (DME) exhibits significant variability, with estimates ranging from 4.2%
to 14.3% in individuals with type 1 diabetes and 1.4% to 5.57% in individuals
with type 2 diabetes.
Thelansis’s “Macular Edema Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Macular Edema treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Macular Edema across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Macular Edema Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment